A single‐dose, randomized, double‐blind, double dummy, placebo and positive‐controlled, five‐way cross‐over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects

ConclusionsLorediplon demonstrated a dose‐dependent improvement in sleep, whereas zolpidem showed a more sustained WASO effect. No next‐day hangover effects were observed. These sleep effects are also consistent with the pharmacokinetic profile of lorediplon. These results warrant clinical trials in patients with insomnia. Copyright © 2014 John Wiley & Sons, Ltd.
Source: Human Psychopharmacology: Clinical and Experimental - Category: Psychiatry Authors: Tags: Research Article Source Type: research